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Classification 









- Signet ring 
- Oncocytic 
- Lymphoepithelioma-like 
Carcinoma with spindle cell differentiation 
(carcinosarcoma, sarcomatoid carcinoma) 
Prostatic intraepithelial neoplasia (PIN) 









Squamous cell carcinoma 
Basal cell tumours: 
Basal cell adenoma 
Basal cell carcinoma 
Neuroendocrine tumours  
Endocrine differentiation within adenocarcinoma  
Carcinoid tumour  
Small cell carcinoma  
Paraganglioma 
Neuroblastoma  
Prostatic stromal tumours  







Malignant fibrous histiocytoma 




Granular cell tumour 
Haemangiopericytoma 






Nephroblastoma (Wilms tumour) 
Rhabdoid tumour 
Germ cell tumours 
Yolk sac tumour 
Seminoma 
Embryonal carcinoma & teratoma 
Choriocarcinoma 
Clear cell adenocarcinoma 
Melanoma 
Metastatic tumours 
TNM classification: The TNM system is the most 
widely used for the stratification of prostatic carinoma 
and is the standard system only for prostate 
adenocarcinomas. The current revision of the TNM 
system is shown in the Table (ICD-O C61): 
Classification of Prostatic Carcinoma: TNM 
classification: 
T-Primary Tumor 
TX Primary tumour cannot be assessed 
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T0 No evidence of primary tumor 
T1 Clinically inapparent tumour, neither palpable nor 
visible by imaging 
T1a Tumour incidental histological finding in 5% or
less of tissue resected 
T1b Tumour incidental histological finding in more 
than 5% of tissue resected 
T1c Tumour identified by needle biopsy (e.g., because 
of elevated PSA) 
T2 Tumour confined within prostate 
T2a Tumour involves one-half of one lobe of less 
T2b Tumour involves more than one-half of one lobe, 
but not both lobes 
T2c Tumour involves both lobes 
T3 Tumour extends through the prostatic capsule 
T3a Extracapsular extension (unilateral or bilateral) 
including microscopic bladder neck involvement 
T3b Tumour invades seminal vesicle(s) 
T4 Tumour is fixed or invades adjacent structures other 
than seminal vesicles: external sphincter, rectum, 
levator muscles and/or pelvic wall 
N-Regional Lymph Nodes 
NX regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M-Distant Metastasis 
M0 No distant metastasis 
M1 Distant metastasis 
M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
 
Stage Grouping 
Stage I T1, T2a N0 M0 
Stage II T2b, T2c N0 M0 
Stage III T3  N0 M0 
Stage IV T4 N0 M0 
  Any T N1 M0 
  Any T Any N M1 
 
Clinics and pathology 
Etiology 
The exact changes between a normal gland and a 
neoplasic one are not yet known. There is increasing 
evidence that predisposing genetic factors are 
implicated. Dietary and environmental factors may also 
play a role in this step of the neoplasic transformation. 
Epidemiology 
Prostate cancer is the second most frequently diagnosed 
cancer of men (914000 new cases, 13.8% of the total) 
and the fifth most common cancer overall with large 
differences between countries.  
In the US, it is estimated that 217730 men will be 
diagnosed with and 32050 men will die of cancer of the 
prostate in 2010 (NCI). In Europe, the number of new 
cases was estimated at 338732 men in 2008 with 70821 
deaths (21.1%). The age-adjusted incidence rate was 
156.0 per 100000 men per year in the US, 110.5 per 
100000 men per year in the Europe and 178.7 men per 
year in the France. 
The worldwide mortality was estimated to 258000 
deaths in 2008. Mortality rates are generally high in 
predominantly black populations, very low in Asia and 
intermediate in Europe and Oceania. 
Prostate cancer rates increase with age. From 2004-
2008, the median age at diagnosis for cancer of the 
prostate was 67 years of age in the US and the median 
age at death for cancer of the prostate was about 80 
years. 
Incidence can be influenced by several risk factors 
including genetic susceptibility, environmental 
exposure (cigarette smoking, alcohol consumption, 
infectious agents, dietary fat, endogenous hormones, ...) 
and difference in health care and cancer registration. 
Large clues on risk factors for prostate cancer are still 
not found. 
Clinics 
Patients with prostate cancer can present with a variety 
of symptoms but are most often asymptomatic. The 
presenting symptoms can be broadly divided into: 
- Bladder outflow obstruction symptoms: poor stream, 
hesitancy, sensation of incomplete emptying, 
frequency, urgency, urinary incontinence due to 
chronic urinary retention, recurrent urinary sepsis... The 
symptoms of bladder outlet obstruction are commonly 
related to concomitant nodular hyperplasia but may 
also result from the prostate cancer, especially if it is 
locally advanced.  
- Symptoms related to local extension of the tumor: 
Pain, haematuria, rectal obstruction or bleeding, 
haemospermia, symptoms of renal failure... 
- Symptoms of metastatic disease: include bone pain
and tenderness. Involvement of the spinal column may
lead to cord compression. Lymphatic involvement from 
prostate cancer may also cause a variety of symptoms 
including lymphoedema (particularly lower limb). 
Digital rectal examination (DRE) should be performed 
and serum PSA measured in patients in whom there is 
clinical suspicion of prostate cancer or in those who 
wished to be screened.  
Prostate-specific marker 
PSA (Prostate-Specific Antigen) represents the best 
serum marker for prostate carcinoma. It is a 34 kD 
glycoprotein which is exclusively secreted from 
epithelial cells of the prostatic ducts. A small portion is 
absorbed into the blood. PSA is useful in diagnostic, 
staging and monitoring men who have prostate 
carcinoma, 4 ng/ml was established as the upper limit 
of normal. An elevation in the total PSA level can be 
the result of benign prostate hyperplasia, prostatitis, 
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prostatic manipulations (DRE, needle biopsy, 
transrectal ultrasound) and intravesical BCG therapy 
rather than prostate carcinoma. 
Despite the reasonable performance of PSA in this 
setting, serum PSA lacks high sensitivity and 
specificity for prostate cancer. To improve this point, 
several approaches have been used including PSA 
density, PSA velocity and the fraction of free serum 
PSA. 
Pathology 
Definitive diagnosis requires biopsies of the prostate, 
using a needle under transrectal ultrasound-Guidance. 
The most prostate cancers are adenocarcinomas (95%) 
which develop from the secretory luminal cells of the 
prostatic gland, 70% arise in the peripheral zone, 15-
20% arise in the central zone and 10-15 % arise in the 
transitional zone. The most prostate cancers are 
multifocal.  
The studies from J. Mc Neal on the zonale topography 
of the prostate and from D. Gleason on the tumoral 
differentiation constituted the basis of 
anatomopathological descriptions of prostate cancers. 
The most widely internationally accepted grading 
model is the Gleason score based on the progressive 
loss of the gland pattern and the increased peritumoural 
stroma invasion. Histopathological grading and 
Gleason scores range as follow:  
Histopathological Grading and Gleason score 
GX: Grade cannot be assessed. 
G1: Well differenciated, Gleason 2-4. 
G2: Moderately differenciated; Gleason score 5-6. 
G3-4: Poorly differentiated/undifferentiated; Gleason 
score 7-10. 
Treatment 
Guidelines exist to help for treatment decisions. The 
choice of a specific treatment is based on the TNM 
staging and the evaluation of the low, intermediate or 
high-risk of prostate cancer. 
Therapeutic options for localized prostate cancer 
- Watchful waiting: or active surveillance is the bst 
option for low risk cancers or for patients with a short 
life expectancy, estimated by age and co-morbidities. 
This therapeutic decision is also based on patient 
general health, potential side effects of treatment and 
patient preference. 
- Radical prostatectomy: is the best treatment in 
localised prostate cancer for patients with at least 10 
years life expectancy. This option is classically used in 
low or intermediate intra-capsular tumors. Otherwise, 
surgical treatment may include not only prostatectomy 
but lymphadenectomy.  
- External-beam radiation therapy (EBRT): is one of 
the primary treatment modalities in localised and  
locally advanced prostate cancer. The introduction of 
3D conformal radiotherapy in the early 1990s allows 
higher doses and safety radiation. The second 
generation 3D technique, intensity modulated 
radiotherapy (IMRT) is now required.  
- Brachytherapy: interstitial permanent brachytherapy 
as monotherapy is indicated for patients with low risk 
cancer. Intermediate risk patient could benefit from the 
brachytherapy if they have only one of the pre-
mentionned risk factors. 
- Androgen deprivation: is not recommended in low 
and intermediate risk disease. 
- Cryotherapy, HIFU (High-intensity focused 
ultrasound) and other focal therapies are not 
recommended as standard initial treatment. 
Therapeutic options for locally advanced prostate 
cancer (T3-4N0M0) 
- Management of locally advanced prostate cancer is 
usually EBRT combined to androgen deprivation 
therapy.  
Actually, a study of Messing and al. suggests that 
immediate androgen deprivation by surgical castration 
or LHRH agonist therapies decrease the risk of 
mortality. The benefit of neo-adjuvant hormone therapy 
remains unclear.  
- Radical prostatectomy in this case is indicated only 
occasionally in a very high selected patients.  
Management of metastatic disease 
Androgen suppression using surgical castration or 
LHRH agonist therapies are the first line. Short-course 
anti-androgen should be used to prevent the disease 
flare up on starting an LHRH agonist. 
Management of castration-refractory prostate cancer 
(CRPC) 
- The patients with castration refractory prostate cancer 
should be considered for second line hormonal 
therapies by anti-androgen, corticosteroid, oestrogen or 
ketoconazol. 
- Docetaxel (Taxotere): Chemotherapy with Docetaxel 
should be envisaged after the failure of all second lines 
hormonal manipulations and in a symptomatic disease. 
In a phase III trial, Tannock et al. demonstrated that 
Docetaxel plus prednisone every 3 weeks improved 
patients survival by 3 months over Mithoxantrone plus 
prednisone. 
- Cabazitaxel (Jevtana): In june 2010, chemotherapy 
with Cabazitaxel was approved by the FDA (US Food 
and Drug Administration) for CRPC previously treated 
with Docetaxel containing regimen. 
- Abiraterone (Zytiga): abiraterone is a new generation 
androgen inhibitor approved for CRPC previously 
treated with Docetaxel.  
- Sipuleucel-T (Provenge): is an immunotherapy 
approved by the FDA since April 2010 for 
asymptomatic or minimally symptomatic prostate 
cancer resistant to standard hormonotherapy.  
- Biphosphonates: mainly zoledronic acid (Zometa) 
may be offered to patients with skeletal metastasis to 
prevent osseous complications. 
Recently, RANK ligand inhibitor, such as denosumab 
has been developed. Denosumab has the effect to slow  
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down metastasis in patients with hormonal therapy and 
also prevents osseous complications much more than 
zoledronic acid. 
- Radiopharmaceuticals: like samarium and strontium, 
can be used for the management of painful osseous 
metastasis. 
Evolution 
The natural history of prostate cancer begins with a 
local tumour burden and a subsequent metastatic 
dissemination, preferentially to bones and the 
inescapable evolution to a castration refractory prostate 
cancer (CRPC). 
Prognosis 
Predicting prognosis is essential for patient decision 
making. Prognostic factors are used to select the 
appropriate treatment option(s) and to predict 
biochemical recurrence (also called PSA failure) after 
radical local therapy. 
The most established independent prognostic factors 
are: the anatomical extend or stage of the disease 
(TNM stage) evaluated by digital rectal examination 
supplemented when necessary by ultrasound or MRI, 
the Gleason score, PSA level and post prostatectomy 
margin status.  
Clinically localized prostate cancer should be classified 
as low, intermediate and high risk. 
- Low risk is corresponding to T1-T2a, Gleason  
- Intermediate risk is T2b, Gleason=7, 10< PSA  
- High risk is =T2c, Gleason >7, PSA>20.  
Imaging investigations are not recommended for men 
with low risk disease, in contrast CT or MRI and bone 
scintigraphy should be considered in high risk disease. 
Other prognostic normograms can be used to predict 
disease progression and patient survival. 
Genetics 
Note 
Several loci associated with an increased familial 
prostate cancer have been mapped to 1q24-25 (HPC1), 
17p11 (HPC2), and Xq27-28 (HPCX). HPC1 
corresponds to RNASEL which encodes an 
endoribonuclease for ssRNA implicated in the 
interferon response to viral infection. 
Cytogenetics 
Note 
Numerous single-nucleotide polymorphisms (SNPs) 
were reported that are associated with cancer risk. 8q24 
is the most frequently gained chromosomal region in 
prostate tumors. Gain in 8q24 region has been 
associated with aggressive tumors, hormone 
independence, and poor prognosis. Although this 
region is frequently amplified in prostate tumors, it 
covered few known or predicted genes. The known 
genes that are closest to 8q24 are FAM84B and MYC.  
Other independent risk loci for prostate cancer risk are 
MSMB (10q11.23); HNF1B (17q12); 
NUDT10/NUDT11 (Xp11.22); 17q12; KLK2/3 
(19q13.33); JAZF1 (7p15.1); 3p12.1; EHBP1 (2p15); 
CTBP2 (10q26.13); SLC22A3 (6q25.3); 22q13. 
CGH (comparative genomic hybridization) was used to 
identify gains or losses of chromosomal regions. The 
most common alterations include chromosome 8 (23%) 
and chromosome 7 (20%). The most commonly 
reported are gains of 2p, 3q, 7q, 8q, 9q, 17q, 20q,and 
Xq, deletions of 2q, 5q, 6q, 8p, 10q, 12p, 13q, 16q, 
17p, 17q, 18q, 21q, and 22q, hyperdiploidy, and 
aneusomy of chromosomes 7 and 17. 
Outlier profile analysis was used to identify the 
TMPRSS2-ERG fusion as the single most prevalent 
gene fusion in prostate cancer (>60%) on 21q22. 
TMPRSS2 encodes for the androgen-activated 
transmembrane protease serine 2 and ERG encodes a 
member of the ETS transcription factor. Other gene 
fusions have been found with ETS genes (including 
ERG, ETV1, ETV4, and ETV5) involving different 5' 
partners (~10%): TMPRSS2 (t(7;21)(p21;q22)), 
SLC45A3 (t(1;7)(q32;p21.2)), ACSL3 
(t(2;7)(q36.1;p21.2)), HERV-K 
(t(7;22)(p21.2;q11.23)), FLJ35294 
(t(7;17)(p21.2;p13.1)), FOXP1 (t(3;7)(p13;p21)), 
EST14 (t(7;14)(p21;q21)), C15orf21 
(t(7;15)(p21.3;q21)), and HNRPA2B1 
(t(7;7)(p21.2;p15)) for ETV1; TMPRSS2 
(t(17;21)(q21;q22)), KLK2 (t(17;19)(q21;q13)), 
CANT1 (inv(17;17)(q22;q25)) and DDX5 
(t(17;17)(q24;q21)) for ETV4; TMPRSS2 
(t(3;21)(q28;q22)) or SLC45A3 (t(1;3)(q32;q28)) for 
ETV5. TMPRSS2-ERG fusions may occur as an early 
event in the development of prostate cancer, but the 
gene fusion is not sufficient to cause cancer formation 
by itself. The prognostic significance of the TMPRSS2-
ERG fusion and other ETS rearrangements in prostate 
cancer is still controversial. Integrative genomic 
profiling was used to identify a narrow deletion on
3p14 is highly associated with TMPRSS2-ERG fusion-
positive tumors. PTEN loss is also associated with the 
presence of the fusion gene TMPRSS2-ERG. 
For more details on the fusion gene TMPRSS2-ERG, 
see the section "Deep insight": TMPRSS2:ETS gene 
fusions in prostate cancer. 
Genes involved and proteins 
Note 
Somatic point mutations in prostate cancer are rare
relative to other tumor types such as glioblastoma, lung 
cancer and melanoma; alterations of gene copy number 
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Protein 
AR gene encodes for the nuclear receptor for the 
androgens, which belongs to the steroid/thyroid 
hormone receptor gene superfamily. This nuclear 
receptor mediates hormone action by binding to 
hormone in the cytoplasm and translocating to the 
nucleus where it dimerizes and binds DNA at 
androgen-responsive gene promoter to modify the 
transcription of target genes. 
Somatic mutations 
Almost all prostate cancers express AR. AR expression 
is maintained during prostate carcinogenesis from 
primary prostate cancer to castration-refractory prostate 
cancer (CRPC). AR was found overexpressed in all 
CRPC and plays a predominant role in the transition 
from androgen-dependent to independent cancer.  
The AR plays a role of a dominant oncogene in 
castration-resistant prostate cancer. AR gene 
amplification has been recovered in ~30% of CRPC. 
AR is also activated by missense mutations 
(frequencies of 10-30%) that modify the scope of 
hormone specificity and/or enhance hormonal response. 
Activation of AR in androgen-independent disease may
also be accomplished by activation of co-regulators that 
interact with AR to activate gene transcription. Another 
potential AR activation mechanism is a ligand-
independent activation by growth-factors or cytokines. 
Several structurally different AR variants with 
divergent biologic activity recently identified could 
emerge as a primary cause of resistance to androgens. 
All of those variants required full-length AR through 
dimerisation to activate endogenous AR target genes 





BRCA2 encodes a large DNA repair protein. As for 
BRCA1, the primary roles of BRCA2 as a tumor 
suppressor gene is to maintain genomic stability 
through DNA repair system and is involved in 
transcriptional regulation process. 
Germinal mutations 
Mutations in BRCA2 and BRCA1 are responsible for 
the largest number of inherited breast cancers and a 
large proportion of ovarian cancers. While in BRCA1 
mutation carriers, the risk increase did not reach 
significance, BRCA2 mutations were associated with a 
significantly increased risk of prostate cancer. Its
mutation accounts for 30-35% of familial breast 
cancers. Prostate cancer screening by PSA assay and 
digital rectal examination annually are recommended at 
age 40-50 years for male carriers of BRCA mutations. 
Somatic mutations 






The gene CDKN1B encodes the cyclin-dependent 
kinase inhibitor p27Kip1 that inhibit cell proliferation. 
Somatic mutations 
Loss or reduced expression of CDKN1B correlates 
with high grade prostate cancer and reduced disease-
free survival. The CDKN1B gene is haploinsufficient, 
so hemizygous deletion reduces the expression of 
CDKN1B and affects its normal function through 
dosage reduction. 
In mouse, concomitant inactivation of PTEN and 
CDKN1B accelerates spontaneous neoplastic 





The Polycomb group gene EZH2 encodes a histone 
lysine methyltransferase which methylates histone H3 
on lysine-9 and dimethyl lysine-27 leading to 
transcriptional repression of the affected target gene. 
Somatic mutations 
The gene EZH2 is frequently up-regulated in advanced 
prostate cancer, in some cases through gene 
amplification. Overexpression of EZH2 confers a poor 





The KLK3 gene encodes a kallikrein of the serine 
protease family. KLK3, like KLK2, is involved in 
semen liquefaction in the normal prostate by degrading 
seminogelin I/II, fibronectin and laminin. Nevertheless, 
KLK3 function can also stimulate prostate cancer cell 
growth and promote metastasis by activating and/or 
degrading a variety of substrates such as PTHRP, 
IGFBP3, IGFBP4 and TGFbeta. Independently of its 
serine protease activity, KLK3 is able to stimulate th  
production of reactive oxygen species in prostate 
cancer cells, probably by binding to a cell surface 
receptor. 
The KLK3 protein is commonly known as the Prostate-
Specific Antigen (PSA) which is the most acceptable 
and broadly used cancer biomarker. Serum level of 
PSA in the clinical setting is useful in the diagnosis and 
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Protein 
The GSTP1 gene encodes an enzyme that plays an 
important role in detoxification by catalyzing the 
conjugation of many hydrophobic and electrophilic 
compounds with reduced glutathione. The GSTP1 gene 
is involved in the DNA methylation of CpG island in 
prostate cancer and other cancers. 
Somatic mutations 
Silencing of GSTP1 expression by promoter 
hypermethylation is an early event in prostate cancer 
initiation, which is seen in up to 70% of PIN lesions 
and in 90-95% of prostate carcinomas. Decreased 
GSTP1 expression may predispose luminal cells to 
increased oxidative damage which in turn result in 
accumulation of genetic changes ultimately resulting in 





The proto-oncogene MYC encodes a transcription 
factor involved in activation of the cell-cycle 
progression and protein biosynthesis which is 
frequently amplified in variety of human malignancies. 
Somatic mutations 
Amplification is observed in approximately 30-40% of 
primary prostate tumors and 90% of metastatic prostate 
cancers and is associated with poor patient outcome. 
The locus at 8q24 was identified as a major 
susceptibility locus in several large-scale genome-wide 
association studies of prostate cancer as well as other 
epithelial cancers. Experiments with mouse models of 
prostate cancer provided strong causal connection 
between the overexpression of MYC and the 





The NKX3.1 gene encodes a prostate-specific 
homeobox transcription factor considered as a putative 
prostate tumor suppressor that is expressed in a largely 
prostate-specific and androgen-regulated manner. 
Germinal mutations 
Human germ line mutations in Nkx3.1, which 
decreases its interaction with DNA, result in genetic 
predisposition to prostate cancer. 
Somatic mutations 
Loss of NKX3.1 protein expression is a common 
finding in 12% prostatic intraepithelial neoplasia (PIN) 
and in 85% human prostate carcinomas. 
Nkx3.1 has been shown to be a critical regulator of 
prostate epithelial differentiation and stem cell function 
in mouse models. NKX3.1 represents a 
haploinsufficient tumor suppressor gene that acts as a 





P53 encode the tumor suppressor most frequently lost 
in human cancer. P53 mutations in primary prostate 
cancer have been detected at a frequency of 10 to 32% 
and are correlated to recurrent prostate cancer. P53 
immunostaining in prostatic needle biopsies predicts 





The tumor suppressor gene PTEN encodes a lipid 
phosphatase that negatively regulates intracellular 
levels of phosphatidylinositol-3,4,5-trisphosphate in 
cells to activate PI3K/Akt signaling pathway. 
Somatic mutations 
17% of primary prostate tumors show a loss of PTEN 
protein and there is significant correlation between 
PTEN loss and Gleason Score and clinical stage. 
PTEN loss is associated with the presence of the fusion 
gene TMPRSS2-ERG. 
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